ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026
Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine tumor of the lung. In patients with metastatic disease, systemic therapies typically have low response rates, and long-term survival is poor. PC frequently expresses DLL3, but whether they respond to the DLL3-targeted bispecific T-cell engager tarlatamab is unknown.
methodsWe analyzed 11 patients with DLL3-high PC treated with tarlatamab at the Memorial Sloan Kettering Cancer Center. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1.
resultsResponse rate was eight of 11 (73%), including one patient with central nervous system-only disease, and the disease control rate was 11 of 11 (100%). All patients experienced a reduction in their measurable disease. One patient had progressed at the time of data cutoff, and the median progression-free survival was not reached. Cytokine release syndrome (CRS) occurred in cycle 1 in nine of 11 patients (82%), including two with grade 3 CRS.
conclusionsTarlatamab reported a high response rate in PC. CRS was common. Tarlatamab is a promising treatment option for patients with PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.